Full-Time

Director Commercial Field Leadership Training

Updated on 3/14/2025

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

No salary listed

Senior, Expert

San Diego, CA, USA

Hybrid model requires this role to work in the office three days per week on average.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree (science or business preferred) or equivalent combination of relevant education and applicable job experience may be considered.
  • MBA preferred.
  • A minimum of 10 years progressively responsible experience in pharmaceutical or medical sales and training, with a minimum of 5 years in a training or sales leadership role.
  • Requires prior pharmaceutical sales experience, pharmaceutical/biotech sales management experience, plus vendor and contract management.
Responsibilities
  • Develop and maintain strong business partnerships with commercial leaders at every level to understand business goals and strategies, and identify opportunities for learning and development programs or support.
  • Evaluate training programs, curriculum, tools, platforms and corresponding training materials for multiple layers of management, to ensure alignment with business goals and strategies.
  • Champion development, delivery, and management of learning journeys across multiple roles/levels.
  • Proactively conduct ongoing feedback discussions with leaders and key stakeholders across the organization to identify opportunities for continuous improvement and relevancy of all learning and development program content.
  • Collaborates and communicates closely with cross-functional partners (e.g., HR).
  • Manage the identification and selection of vendors, as well as subsequent relationships and projects related to learning and development programs.
  • Attend appropriate training classes to maintain an advanced level of knowledge.
  • Forecast future needs, manage budget, and achieve financial targets.
Desired Qualifications
  • Experience with product launches and Long-Term Care and Account Management experience is highly desired.
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these conditions while also promoting diversity and inclusion within their operations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's DAYBUE is now available for treating Rett syndrome in the U.S.
  • The partnership with Neuren Pharmaceuticals strengthens Acadia's position in the rare disease market.
  • Increased focus on personalized medicine benefits Acadia's tailored CNS disorder therapies.

What critics are saying

  • A class action lawsuit could lead to financial liabilities and reputational damage.
  • Increased competition in CNS treatments may impact Acadia's market share.
  • Reliance on partnerships poses risks if collaborations face challenges or fail.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on CNS disorders with a strong pipeline of small molecule drugs.
  • The company has a unique partnership with Stoke Therapeutics for RNA-based therapies.
  • Acadia's documentary series raises awareness for Rett syndrome, enhancing its community engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

2%
Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Yahoo Finance
Aug 15th, 2024
Ryan Reynolds Announces More To Parkinson'S(R) Campaign

Ryan & Tammy Reynolds (Photo: Business Wire)Acadia Parkinson's Fact Sheet-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their familySAN DIEGO, August 14, 2024--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson’s disease – Parkinson’s-related hallucinations and delusions.Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to 90% of people currently do not proactively tell their physicians about these symptoms.1-3 By sharing their experiences caring for Ryan’s father, James "Jim" Reynolds, who passed away nearly a decade ago, Ryan and his mother Tammy, aim to raise awareness, educate and drive conversation between people with Parkinson’s disease, their families and their doctors about how best to talk about and treat these non-motor symptoms."My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease," Reynolds explains. "Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease."This press release features multimedia